海正药业
(600267)
| 流通市值：132.16亿 | | | 总市值：132.23亿 |
| 流通股本：11.98亿 | | | 总股本：11.99亿 |
| 报告期 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 7,922,794,186.82 | 5,250,334,553.43 | 2,631,818,241.67 | 10,340,247,008.47 |
| 营业收入 | 7,922,794,186.82 | 5,250,334,553.43 | 2,631,818,241.67 | 10,340,247,008.47 |
| 二、营业总成本 | 7,073,625,021.67 | 4,675,003,997.9 | 2,362,401,236.88 | 9,570,389,705.32 |
| 营业成本 | 4,358,649,302.4 | 2,943,459,569.95 | 1,522,948,352.79 | 5,950,189,248.09 |
| 税金及附加 | 83,988,165.73 | 52,043,017.2 | 31,525,849.69 | 107,827,516.9 |
| 销售费用 | 1,609,805,985.09 | 1,063,975,689.75 | 504,930,925.85 | 2,128,788,534.69 |
| 管理费用 | 587,921,517.94 | 373,562,587.03 | 191,273,212.69 | 896,955,589.19 |
| 研发费用 | 372,154,095.37 | 202,367,069.77 | 92,429,291.9 | 357,688,684.68 |
| 财务费用 | 61,105,955.14 | 39,596,064.2 | 19,293,603.96 | 128,940,131.77 |
| 其中:利息费用 | 78,464,830.99 | 54,716,456.28 | 28,650,109.33 | 155,899,507.05 |
| 其中:利息收入 | 17,064,722.46 | 14,268,500.13 | 10,280,693.95 | 23,998,256.87 |
| 三、其他经营收益 | | | | |
| 加:公允价值变动收益 | -36,370,692.67 | -35,878,704.73 | -2,565,091.57 | -14,926,284.66 |
| 加:投资收益 | -34,534,648.03 | -33,045,798.2 | -14,858,735.54 | 157,458,101.15 |
| 资产处置收益 | 2,340,902.89 | 305,012.36 | 113,471.7 | 722,661.2 |
| 资产减值损失(新) | -162,306,635.28 | -99,263,012.41 | -33,027,181.14 | -219,020,280.63 |
| 信用减值损失(新) | -44,600,711.67 | -43,199,375.12 | 1,984,974.24 | -86,750,100.09 |
| 其他收益 | 69,026,284.75 | 55,210,250.62 | 29,407,445.65 | 113,992,631.02 |
| 四、营业利润 | 642,723,665.14 | 419,458,928.05 | 250,471,888.13 | 721,334,031.14 |
| 加:营业外收入 | 7,572,600.25 | 6,742,125 | 226,230.25 | 7,457,918.79 |
| 减:营业外支出 | 30,561,126.79 | 21,900,871.41 | 1,312,437.17 | 10,719,878.44 |
| 五、利润总额 | 619,735,138.6 | 404,300,181.64 | 249,385,681.21 | 718,072,071.49 |
| 减:所得税费用 | 151,677,328.5 | 99,386,552.1 | 52,587,789.48 | 126,760,200.9 |
| 六、净利润 | 468,057,810.1 | 304,913,629.54 | 196,797,891.73 | 591,311,870.59 |
| (一)按经营持续性分类 | | | | |
| 持续经营净利润 | 468,057,810.1 | 304,913,629.54 | 196,797,891.73 | - |
| (二)按所有权归属分类 | | | | |
| 归属于母公司股东的净利润 | 460,929,192.8 | 299,070,584.84 | 194,227,169.89 | 601,182,827.25 |
| 少数股东损益 | 7,128,617.3 | 5,843,044.7 | 2,570,721.84 | -9,870,956.66 |
| 扣除非经常损益后的净利润 | 490,513,193.75 | 321,225,615.75 | 182,165,119.51 | 430,305,723.33 |
| 七、每股收益 | | | | |
| (一)基本每股收益 | 0.4 | 0.26 | 0.17 | - |
| (二)稀释每股收益 | 0.4 | 0.26 | 0.17 | - |
| 八、其他综合收益 | -1,325,403.18 | -605,808.91 | -324,622.95 | 952,422.72 |
| 归属于母公司股东的其他综合收益 | -1,325,403.18 | -605,808.91 | -324,622.95 | 952,422.72 |
| 九、综合收益总额 | 466,732,406.92 | 304,307,820.63 | 196,473,268.78 | 592,264,293.31 |
| 归属于母公司股东的综合收益总额 | 459,603,789.62 | 298,464,775.93 | 193,902,546.94 | 602,135,249.97 |
| 归属于少数股东的综合收益总额 | 7,128,617.3 | 5,843,044.7 | 2,570,721.84 | -9,870,956.66 |
| 公告日期 | 2025-10-28 | 2025-08-26 | 2025-04-17 | 2025-03-29 |
| 审计意见(境内) | | | | 标准无保留意见 |